Generalized morphea following the COVID vaccine: A series of two patients and a bibliographic review.
COVID
cross-reactivity
immunorelated
morphea
vaccination
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
13
06
2022
received:
25
03
2022
accepted:
26
06
2022
pubmed:
12
7
2022
medline:
9
9
2022
entrez:
11
7
2022
Statut:
ppublish
Résumé
The appearance of morphea after vaccination has been reported to date as single and deep lesions that appear exactly at the site of the skin puncture. It was therefore postulated that the origin could be the trauma related to the injection. The aim of this article is to review the various hypotheses offered in the published literature about generalized morphea following vaccination. We present two cases of generalized morphea after COVID-19 vaccination and review the published literature on immune-related cutaneous reactions. As previously reported, antigenic cross-reactivity between vaccine spike proteins and human tissues could cause certain immune-mediated diseases, including generalized morphea. Herein we report two cases of generalized morphea probably induced by the COVID-19 vaccine, given the temporal relationship with its administration. In summary, environmental factors such as vaccination against SARS-COV-2 could induce an immune system dysregulation, which would have an important role in the pathogenesis of morphea. We present two cases of generalized morphea probably induced by the COVID-19 vaccine, given the time elapsed between vaccination and the onset of the skin lesions.
Identifiants
pubmed: 35811413
doi: 10.1111/dth.15709
pmc: PMC9349378
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15709Informations de copyright
© 2022 The Authors. Dermatologic Therapy published by Wiley Periodicals LLC.
Références
Dermatol Ther. 2022 Sep;35(9):e15709
pubmed: 35811413
Int J Dermatol. 2022 May;61(5):639-641
pubmed: 35073411
J Eur Acad Dermatol Venereol. 2022 Feb;36(2):172-180
pubmed: 34661927
Br J Dermatol. 2022 Jan;186(1):142-152
pubmed: 34254291
J Am Acad Dermatol. 2001 Oct;45(4):614-5
pubmed: 11568757
J Eur Acad Dermatol Venereol. 2021 Dec;35(12):2456-2461
pubmed: 34459036
Lancet. 2020 Nov 14;396(10262):1595-1606
pubmed: 33065034
J Am Acad Dermatol. 2021 Jul;85(1):46-55
pubmed: 33838206
Pediatr Dermatol. 2015 Nov-Dec;32(6):865-6
pubmed: 26584695
J Dermatol. 2002 Dec;29(12):781-5
pubmed: 12532044
Pediatr Dermatol. 2012 Jul-Aug;29(4):525-7
pubmed: 21854420
J Eur Acad Dermatol Venereol. 2002 Sep;16(5):516-8
pubmed: 12428851
Front Med (Lausanne). 2021 Oct 20;8:728411
pubmed: 34746174
Pediatr Dermatol. 2006 Sep-Oct;23(5):484-7
pubmed: 17014648
Int J Dermatol. 2022 Mar;61(3):377-378
pubmed: 34783020